University College London: Weight Loss Drug's Heart Benefits Extend to People With Heart Failure
August 24, 2024
August 24, 2024
LONDON, England, Aug. 24 (TNSres) -- The University College London issued the following news:
The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also have heart failure, according to a new study led by UCL's Professor John Deanfield.
The results follow previous research* from the same international team finding that weekly injections . . .
The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also have heart failure, according to a new study led by UCL's Professor John Deanfield.
The results follow previous research* from the same international team finding that weekly injections . . .